Current advances in bispecific T cell–engaging therapies

Emmanuel Owusu Ansah, Benard Ansong, Foster Kyei

Abstract


The emergence of bispecific antibodies has transformed cancer immunotherapy, highlighting increased clinical efficacy, especially in hematological malignancies. These innovative molecules uniquely target two distinct tumor antigens or separate epitopes simultaneously, demonstrating potent antitumor activity across various cancers. Despite their promise, challenges like rapid drug clearance, off-target effects, and cytokine release syndrome hinder their widespread therapeutic application. Recent engineering advancements in bispecific antibody systems aim to overcome these challenges, broadening therapeutic coverage. This review provides insights into the latest clinical and preclinical progress in bispecific immunotherapy. In addition, we outline key challenges associated with this technique and explore emerging strategies to address these obstacles.

 

Received on, 10 February 2025

Accepted on, 06 April 2025

Published on, 23 April 2025


Keywords


Bispecific, immunotherapy, cancer, cytokine, antibodies

Full Text:

PDF

References


Salvaris R, Ong J, Gregory GP. Bispecific Antibodies: A Review of Development, Clinical Efficacy and Toxicity in B-Cell Lymphomas. J Pers Med. 2021 Apr 29;11(5):355.

Henricks LM, Schellens JHM, Huitema ADR, Beijnen JH. The use of combinations of monoclonal antibodies in clinical oncology. Cancer Treat Rev. 2015 Dec;41(10):859–67.

Han Y, Liu D, Li L. PD-1/PD-L1 pathway: current researches in cancer. Am J Cancer Res. 2020;10(3).

Ma J, Mo Y, Tang M, Shen J, Qi Y, Zhao W, et al. Bispecific Antibodies: From Research to Clinical Application. Front Immunol. 2021 May 5;12.

Acheampong DO, Adokoh CK, Ampomah P, Agyirifor DS, Dadzie I, Ackah FA, et al. Bispecific Antibodies (bsAbs): Promising Immunotherapeutic Agents for Cancer Therapy. Protein Pept Lett. 2017 May 10;24(5):456–65.

Ma Y, Xue J, Zhao Y, Zhang Y, Huang Y, Yang Y, et al. Phase I trial of KN046, a novel bispecific antibody targeting PD-L1 and CTLA-4 in patients with advanced solid tumors. J Immunother Cancer. 2023 Jun;11(6):e006654.

Wu Y, Yi M, Zhu S, Wang H, Wu K. Recent advances and challenges of bispecific antibodies in solid tumors. Exp Hematol Oncol. 2021 Dec 18;10(1):56.

Brinkmann U, Kontermann RE. Bispecific antibodies. Science (1979). 2021 May 28;372(6545):916–7.

Moreau P, Garfall AL, van de Donk NWCJ, Nahi H, San-Miguel JF, Oriol A, et al. Teclistamab in Relapsed or Refractory Multiple Myeloma. New England Journal of Medicine. 2022 Aug 11;387(6):495–505.

Lesokhin AM, Tomasson MH, Arnulf B, Bahlis NJ, Miles Prince H, Niesvizky R, et al. Elranatamab in relapsed or refractory multiple myeloma: phase 2 MagnetisMM-3 trial results. Nat Med. 2023 Sep 15;29(9):2259–67.

Keam SJ. Talquetamab: First Approval. Drugs. 2023 Oct 4;83(15):1439–45.

Scott LJ, Kim ES. Emicizumab-kxwh: First Global Approval. Drugs. 2018 Feb 22;78(2):269–74.

Shirley M. Faricimab: First Approval. Drugs. 2022 May 26;82(7):825–30.

Wu B, Jug R, Luedke C, Su P, Rehder C, McCall C, et al. Lineage Switch Between B-Lymphoblastic Leukemia and Acute Myeloid Leukemia Intermediated by “Occult” Myelodysplastic Neoplasm. Am J Clin Pathol. 2017 Aug;148(2):136–47.

Li H, Er Saw P, Song E. Challenges and strategies for next-generation bispecific antibody-based antitumor therapeutics. Cell Mol Immunol. 2020 May 20;17(5):451–61.

Underwood DJ, Bettencourt J, Jawad Z. The manufacturing considerations of bispecific antibodies. Expert Opin Biol Ther. 2022 Aug 3;22(8):1043–65.

Zhang T, Lin Y, Gao Q. Bispecific antibodies targeting immunomodulatory checkpoints for cancer therapy. Cancer Biol Med. 2023 Mar 24;20(3):181–95.

Yu GH, Li AM, Li X, Yang Z, Peng H. Bispecific antibody suppresses osteosarcoma aggressiveness through regulation of NF-κB signaling pathway. Tumor Biology. 2017 Jun 20;39(6):101042831770557.

Zhong Z, Zhang M, Ning Y, Mao G, Li X, Deng Q, et al. Development of a bispecific antibody targeting PD-L1 and TIGIT with optimal cytotoxicity. Sci Rep. 2022 Oct 26;12(1):18011.

Esfandiari A, Cassidy S, Webster RM. Bispecific antibodies in oncology. Nat Rev Drug Discov. 2022 Jun 4;21(6):411–2.

Löffler A, Kufer P, Lutterbüse R, Zettl F, Daniel PT, Schwenkenbecher JM, et al. A recombinant bispecific single-chain antibody, CD19 x CD3, induces rapid and high lymphoma-directed cytotoxicity by unstimulated T lymphocytes. Blood. 2000;95(6).

Ansah EO, Baah A, Agyenim EB. Vaccine Boosting CAR-T Cell Therapy: Current and Future Strategies. Adv Cell Gene Ther. 2023 Jan 31;2023:1–9.

Viardot A, Goebeler ME, Hess G, Neumann S, Pfreundschuh M, Adrian N, et al. Phase 2 study of the bispecific T-cell engager (BiTE) antibody blinatumomab in relapsed/refractory diffuse large B-cell lymphoma. Blood [Internet]. 2016 Mar 17;127(11):1410–6. Available from: https://www.ncbi.nlm.nih.gov/pubmed/26755709

Simão DC, Zarrabi KK, Mendes JL, Luz R, Garcia JA, Kelly WK, et al. Bispecific T-Cell Engagers Therapies in Solid Tumors: Focusing on Prostate Cancer. Cancers (Basel). 2023 Feb 23;15(5):1412.

Subklewe M. BiTEs better than CAR T cells. Blood Adv. 2021 Jan 26;5(2):607–12.

Buzzetti M, Gerlinger M. Assessing the toxicity of bispecific antibodies. Nat Biomed Eng. 2023 Dec 22;8(4):339–40.

Wang DR, Wu XL, Sun YL. Therapeutic targets and biomarkers of tumor immunotherapy: response versus non-response. Signal Transduct Target Ther [Internet]. 2022 Apr;7:1–27. Available from: https://www.nature.com/articles/s41392-022-01136-2#Fig1

Li J, Piskol R, Ybarra R, Chen YJJ, Li J, Slaga D, et al. CD3 bispecific antibody–induced cytokine release is dispensable for cytotoxic T cell activity. Sci Transl Med. 2019 Sep 4;11(508).

Wang K, Wei G, Liu D. CD19: a biomarker for B cell development, lymphoma diagnosis and therapy. Exp Hematol Oncol. 2012 Dec 29;1(1):36.

Shimabukuro-Vornhagen A, Gödel P, Subklewe M, Stemmler HJ, Schlößer HA, Schlaak M, et al. Cytokine release syndrome. J Immunother Cancer. 2018 Dec 15;6(1):56.

Slaga D, Ellerman D, Lombana TN, Vij R, Li J, Hristopoulos M, et al. Avidity-based binding to HER2 results in selective killing of HER2-overexpressing cells by anti-HER2/CD3. Sci Transl Med. 2018 Oct 17;10(463).

Singh A, Dees S, Grewal IS. Overcoming the challenges associated with CD3+ T-cell redirection in cancer. Br J Cancer. 2021 Mar 16;124(6):1037–48.

Bacac M, Fauti T, Sam J, Colombetti S, Weinzierl T, Ouaret D, et al. A Novel Carcinoembryonic Antigen T-Cell Bispecific Antibody (CEA TCB) for the Treatment of Solid Tumors. Clinical Cancer Research. 2016 Jul 1;22(13):3286–97.

Zhu X yi, Li Q xiao, Kong Y, Huang K ke, Wang G, Wang Y ji, et al. A novel human single-domain antibody-drug conjugate targeting CEACAM5 exhibits potent in vitro and in vivo antitumor activity. Acta Pharmacol Sin. 2024 Mar 29;45(3):609–18.

Simão DC, Zarrabi KK, Mendes JL, Luz R, Garcia JA, Kelly WK, et al. Bispecific T-Cell Engagers Therapies in Solid Tumors: Focusing on Prostate Cancer. Cancers (Basel). 2023 Feb 23;15(5):1412.

Oates J, Hassan NJ, Jakobsen BK. ImmTACs for targeted cancer therapy: Why, what, how, and which. Mol Immunol. 2015 Oct;67(2):67–74.

Howlett S, Carter TJ, Shaw HM, Nathan PD. Tebentafusp: a first-in-class treatment for metastatic uveal melanoma. Ther Adv Med Oncol. 2023 Jan 21;15.

Pulte ED, Vallejo J, Przepiorka D, Nie L, Farrell AT, Goldberg KB, et al. FDA Supplemental Approval: Blinatumomab for Treatment of Relapsed and Refractory Precursor B-Cell Acute Lymphoblastic Leukemia. Oncologist [Internet]. 2018 Nov 1;23(11):1366–71. Available from: https://www.ncbi.nlm.nih.gov/pubmed/30018129.

Mocquot P, Mossazadeh Y, Lapierre L, Pineau F, Despas F. The pharmacology of blinatumomab: state of the art on pharmacodynamics, pharmacokinetics, adverse drug reactions and evaluation in clinical trials. J Clin Pharm Ther. 2022 Sep 29;47(9):1337–51.

Boissel N, Chiaretti S, Papayannidis C, Ribera JM, Bassan R, Sokolov AN, et al. Real-world use of blinatumomab in adult patients with B-cell acute lymphoblastic leukemia in clinical practice: results from the NEUF study. Blood Cancer J. 2023 Jan 4;13(1):2.

Burt R, Warcel D, Fielding AK. Blinatumomab, a bispecific B-cell and T-cell engaging antibody, in the treatment of B-cell malignancies. Hum Vaccin Immunother. 2019 Mar 4;15(3):594–602.

Zhou S, Liu M, Ren F, Meng X, Yu J. The landscape of bispecific T cell engager in cancer treatment. Biomark Res. 2021 May 26;9(1):38.

Jabbour E, Kantarjian H. Chemoimmunotherapy as a new standard of care for Burkitt leukaemia/lymphoma. The Lancet. 2016 Jun;387(10036):2360–1.

Zhao Y, Aldoss I, Qu C, Crawford JC, Gu Z, Allen EK, et al. Tumor-intrinsic and -extrinsic determinants of response to blinatumomab in adults with B-ALL. Blood. 2020 Apr;137:471–84.

Li Y, Moriyama T, Yoshimura S, Zhao X, Li Z, Yang X, et al. PAX5 epigenetically orchestrates CD58 transcription and modulates blinatumomab response in acute lymphoblastic leukemia. Sci Adv. 2022 Dec 16;8(50).

Haddox CL, Mangaonkar AA, Chen D, Shi M, He R, Oliveira JL, et al. Blinatumomab-induced lineage switch of B-ALL with t(4:11)(q21;q23) KMT2A/AFF1 into an aggressive AML: pre- and post-switch phenotypic, cytogenetic and molecular analysis. Blood Cancer J. 2017 Sep 15;7(9):e607–e607.

Rayes A, McMasters RL, O’Brien MM. Lineage Switch in MLL‐Rearranged Infant Leukemia Following CD19‐Directed Therapy. Pediatr Blood Cancer. 2016 Jun 23;63(6):1113–5.

Jacoby E, Nguyen SM, Fountaine TJ, Welp K, Gryder B, Qin H, et al. CD19 CAR immune pressure induces B-precursor acute lymphoblastic leukaemia lineage switch exposing inherent leukaemic plasticity. Nat Commun. 2016 Jul 27;7(1):12320.

Stass S, Mirro J, Melvin S, Pui CH, Murphy SB, Williams D. Lineage switch in acute leukemia. Blood. 1984;64(3).

Perna F, Sadelain M. Myeloid leukemia switch as immune escape from CD19 chimeric antigen receptor (CAR) therapy. Transl Cancer Res. 2016 Aug;5(S2):S221–5.

Aldulescu M, Leuer K, Jennings LJ, Yap KL, Gong S. Lineage switch from acute myeloid leukemia to B‐lymphoblastic lymphoma with an acquired PIK3R1 loss‐of‐function mutation. Am J Hematol. 2023 Jan 4;98(1).

Dorantes-Acosta E, Pelayo R. Lineage Switching in Acute Leukemias: A Consequence of Stem Cell Plasticity? Bone Marrow Res. 2012 Jul 19;2012:1–18.

Yang W, Xie S, Li Y, Wang J, Xiao J, Huang K, et al. Lineage switch from lymphoma to myeloid neoplasms: First case series from a single institution. Open Medicine. 2022 Sep 8;17(1):1466–72.

Pui CH, Raimondi SC, Behm FG, Ochs J, Furman WL, Bunin NJ, et al. Shifts in blast cell phenotype and karyotype at relapse of childhood lymphoblastic leukemia. Blood. 1986;68(6).

Zuna J, Cavé H, Eckert C, Szczepanski T, Meyer C, Mejstrikova E, et al. Childhood secondary ALL after ALL treatment. Leukemia. 2007 Jul 26;21(7):1431–5.

Li LZ, Sun Q, Fang Y, Yang LJ, Xu ZY, Hu JH, et al. A report on Lineage switch at relapse of CD19 CAR-T therapy for Philadelphia chromosome-positive B-precursor acute lymphoblastic leukemia. Chin Med J (Engl). 2020 Aug 20;133(16):2001–3.

Rayes A, McMasters RL, O’Brien MM. Lineage Switch in MLL‐Rearranged Infant Leukemia Following CD19‐Directed Therapy. Pediatr Blood Cancer. 2016 Jun 23;63(6):1113–5.

Wölfl M, Rasche M, Eyrich M, Schmid R, Reinhardt D, Schlegel PG. Spontaneous reversion of a lineage switch following an initial blinatumomab-induced ALL-to-AML switch in MLL-rearranged infant ALL. Blood Adv. 2018 Jun 26;2(12):1382–5.

Iacobucci I, Mullighan CG. KMT2A- rearranged leukemia: the shapeshifter. Blood. 2022 Oct 27;140(17):1833–5.

Shimony S, Luskin MR. Unraveling KMT2A -rearranged ALL. Blood. 2023 Nov 23;142(21):1764–6.

Meyer C, Larghero P, Almeida Lopes B, Burmeister T, Gröger D, Sutton R, et al. The KMT2A recombinome of acute leukemias in 2023. Leukemia. 2023 May 5;37(5):988–1005.

He RR, Nayer Z, Hogan M, Cuevo RS, Woodward K, Heyer D, et al. Immunotherapy- (Blinatumomab-) Related Lineage Switch of KMT2A/AFF1 Rearranged B-Lymphoblastic Leukemia into Acute Myeloid Leukemia/Myeloid Sarcoma and Subsequently into B/Myeloid Mixed Phenotype Acute Leukemia. Case Rep Hematol. 2019 Dec 7;2019:1–4.

Fournier E, Inchiappa L, Delattre C, Pignon JM, Danicourt F, Bemba M, et al. Increased risk of adverse acute myeloid leukemia after anti-CD19-targeted immunotherapies in KMT2A -rearranged acute lymphoblastic leukemia: a case report and review of the literature. Leuk Lymphoma. 2019 Jun 7;60(7):1827–30.

Nagel I, Bartels M, Duell J, Oberg HH, Ussat S, Bruckmueller H, et al. Hematopoietic stem cell involvement in BCR-ABL1–positive ALL as a potential mechanism of resistance to blinatumomab therapy. Blood. 2017 Nov 2;130(18):2027–31.

Zoghbi A, zur Stadt U, Winkler B, Müller I, Escherich G. Lineage switch under blinatumomab treatment of relapsed common acute lymphoblastic leukemia without MLL rearrangement. Pediatr Blood Cancer. 2017 Nov 28;64(11).

Du J, Chisholm KM, Tsuchiya K, Leger K, Lee BM, Rutledge JC, et al. Lineage Switch in an Infant B-Lymphoblastic Leukemia With t(1;11)(p32;q23); KMT2A/EPS15 , Following Blinatumomab Therapy. Pediatric and Developmental Pathology. 2021 Aug 22;24(4):378–82.

Meyer C, Hofmann J, Burmeister T, Gröger D, Park TS, Emerenciano M, et al. The MLL recombinome of acute leukemias in 2013. Leukemia. 2013 Nov 30;27(11):2165–76.

Piciocchi A, Messina M, Elia L, Vitale A, Soddu S, Testi AM, et al. Prognostic impact of KMT2A‐AFF1 ‐positivity in 926 BCR‐ABL1 ‐negative B‐lineage acute lymphoblastic leukemia patients treated in GIMEMA clinical trials since 1996. Am J Hematol. 2021 Sep 9;96(9).

Richard-Carpentier G, Kantarjian HM, Tang G, Yin CC, Khoury JD, Issa GC, et al. Outcomes of acute lymphoblastic leukemia with KMT2A ( MLL ) rearrangement: the MD Anderson experience. Blood Adv. 2021 Dec 14;5(23):5415–9.

Newman H, Tasian SK. The Brilliant Success of Blinatumomab for Babies With Acute Lymphoblastic Leukemia. The Hematologist. 2023;20(6).

van der Sluis IM, de Lorenzo P, Kotecha RS, Attarbaschi A, Escherich G, Nysom K, et al. Blinatumomab Added to Chemotherapy in Infant Lymphoblastic Leukemia. New England Journal of Medicine. 2023 Apr 27;388(17):1572–81.

Qi Y, Liu H, Li X, Shi Y, Mu J, Li J, et al. Blinatumomab as salvage therapy in patients with relapsed/refractory B-ALL who have failed/progressed after anti-CD19-CAR T therapy. Ann Med. 2023 Dec 12;55(1).

Shah BD, Bishop MR, Oluwole OO, Logan AC, Baer MR, Donnellan WB, et al. KTE-X19 anti-CD19 CAR T-cell therapy in adult relapsed/refractory acute lymphoblastic leukemia: ZUMA-3 phase 1 results. Blood. 2021 Jul 8;138(1):11–22.

Przepiorka D, Ko CW, Deisseroth A, Yancey CL, Candau-Chacon R, Chiu HJ, et al. FDA Approval: Blinatumomab. Clinical Cancer Research. 2015 Sep 15;21(18):4035–9.

Rodriguez‐Merchan EC, Valentino LA. Emicizumab: Review of the literature and critical appraisal. Haemophilia. 2019 Jan 15;25(1):11–20.

Shah V, McNatty A, Simpson L, Ofori H, Raheem F. Amivantamab-Vmjw: A Novel Treatment for Patients with NSCLC Harboring EGFR Exon 20 Insertion Mutation after Progression on Platinum-Based Chemotherapy. Biomedicines. 2023 Mar 20;11(3):950.

Hwa PG, Carlson DD, R. Starr PBJ. Tebentafusp-tebn: A Novel Bispecific T-Cell Engager for Metastatic Uveal Melanoma. J Adv Pract Oncol. 2022 Sep 1;13(7):717–23.

Shirley M. Faricimab: First Approval. Drugs. 2022 May 26;82(7):825–30.

Shultes KC. Mosunetuzumab-axgb (LunsumioTM). Oncology Times. 2023;45(16).

Keam SJ. Cadonilimab: First Approval. Drugs. 2022 Aug 20;82(12):1333–9.

Martino EA, Bruzzese A, Labanca C, Mendicino F, Lucia E, Olivito V, et al. Teclistamab‐cqyv in multiple myeloma. Eur J Haematol. 2024 Mar 17;112(3):320–7.

Lovell A. Epcoritamab-bysp (EpkinlyTM). Oncology Times. 2023;45(18).

Riaz R, Khan A, Siddiqui T. Epcoritamab-bysp (Epkinly) – A phenomenal breakthrough in the treatment of diffuse large B-cell lymphoma. Rare Tumors. 2023 Apr 31;15.

Pelosci A. FDA Gives Talquetamab Accelerated Approval for R/R Multiple Myeloma. Cancer Network, NA-NA. 2023;

Dhillon S. Elranatamab: First Approval. Drugs. 2023 Nov 4;83(17):1621–7.

Blair HA. Odronextamab: First Approval. Drugs. 2024 Dec 19;84(12):1651–8.

Lee JB, Kim HR, Ha SJ. Immune Checkpoint Inhibitors in 10 Years: Contribution of Basic Research and Clinical Application in Cancer Immunotherapy. Immune Netw. 2022;22(1).

Razaghi A, Durand-Dubief M, Brusselaers N, Björnstedt M. Combining PD-1/PD-L1 blockade with type I interferon in cancer therapy. Front Immunol. 2023 Aug 24;14.

Meybodi SM, Farasati Far B, Pourmolaei A, Baradarbarjastehbaf F, Safaei M, Mohammadkhani N, et al. Immune checkpoint inhibitors promising role in cancer therapy: clinical evidence and immune-related adverse events. Medical Oncology. 2023 Jul 15;40(8):243.

Wang Y, Yang S, Wan L, Ling W, Chen H, Wang J. New developments in the mechanism and application of immune checkpoint inhibitors in cancer therapy (Review). Int J Oncol. 2023 Jun 12;63(1):86.

Bonaventura P, Shekarian T, Alcazer V, Valladeau-Guilemond J, Valsesia-Wittmann S, Amigorena S, et al. Cold Tumors: A Therapeutic Challenge for Immunotherapy. Front Immunol. 2019 Feb 8;10.

Wang L, Geng H, Liu Y, Liu L, Chen Y, Wu F, et al. Hot and cold tumors: Immunological features and the therapeutic strategies. MedComm (Beijing). 2023 Oct 26;4(5).

Blanco B, Domínguez-Alonso C, Alvarez-Vallina L. Bispecific Immunomodulatory Antibodies for Cancer Immunotherapy. Clinical Cancer Research. 2021 Oct 15;27(20):5457–64.

Wang Y, Du J, Gao Z, Sun H, Mei M, Wang Y, et al. Evolving landscape of PD-L2: bring new light to checkpoint immunotherapy. Br J Cancer. 2023 Mar 30;128(7):1196–207.

Takehara T, Wakamatsu E, Machiyama H, Nishi W, Emoto K, Azuma M, et al. PD-L2 suppresses T cell signaling via coinhibitory microcluster formation and SHP2 phosphatase recruitment. Commun Biol. 2021 May 14;4(1):581.

Kotanides H, Li Y, Malabunga M, Carpenito C, Eastman SW, Shen Y, et al. Bispecific Targeting of PD-1 and PD-L1 Enhances T-cell Activation and Antitumor Immunity. Cancer Immunol Res. 2020 Oct 1;8(10):1300–10.

Yearley JH, Gibson C, Yu N, Moon C, Murphy E, Juco J, et al. PD-L2 Expression in Human Tumors: Relevance to Anti-PD-1 Therapy in Cancer. Clinical Cancer Research. 2017 Jun 15;23(12):3158–67.

Wei J, Montalvo-Ortiz W, Yu L, Krasco A, Olson K, Rizvi S, et al. CD22-targeted CD28 bispecific antibody enhances antitumor efficacy of odronextamab in refractory diffuse large B cell lymphoma models. Sci Transl Med. 2022 Nov 9;14(670).

Ke H, Zhang F, Wang J, Xiong L, An X, Tu X, et al. HX009, a novel BsAb dual targeting PD1 x CD47, demonstrates potent anti-lymphoma activity in preclinical models. Sci Rep. 2023 Apr 3;13(1):5419.

Dovedi SJ, Elder MJ, Yang C, Sitnikova SI, Irving L, Hansen A, et al. Design and Efficacy of a Monovalent Bispecific PD-1/CTLA4 Antibody That Enhances CTLA4 Blockade on PD-1+ Activated T Cells. Cancer Discov. 2021 May 1;11(5):1100–17.

Geuijen C, Tacken P, Wang LC, Klooster R, van Loo PF, Zhou J, et al. A human CD137×PD-L1 bispecific antibody promotes anti-tumor immunity via context-dependent T cell costimulation and checkpoint blockade. Nat Commun. 2021 Jul 21;12(1):4445.

Lin W, Zhang Y, Yang Y, Lin B, Zhu M, Xu J, et al. Anti-PD-1/Her2 Bispecific Antibody IBI315 Enhances the Treatment Effect of Her2-Positive Gastric Cancer through Gasdermin B-Cleavage Induced Pyroptosis. Advanced Science. 2023;10(30).

Perez-Santos M. Bispecific anti-PD-1/CTLA-4 Antibody for Advanced Solid Tumors. Pharm Pat Anal. 2020 Sep 22;9(5):149–54.




DOI: https://dx.doi.org/10.21622/AMPDR.2025.05.1.1222

Refbacks

  • There are currently no refbacks.


Copyright (c) 2025 Emmanuel Owusu Ansah, Benard Ansong, Foster Kyei

Advances in Medical, Pharmaceutical and Dental Research

E-ISSN: 2812-4898

P-ISSN: 2812-488X

 

Published by:

Academy Publishing Center (APC)

Arab Academy for Science, Technology and Maritime Transport (AASTMT)

Alexandria, Egypt

ampdr@aast.edu